Literature DB >> 14504670

Some aspects of interindividual variations in the metabolism of xenobiotics.

V Tamási1, L Vereczkey, A Falus, K Monostory.   

Abstract

Differences in drug metabolism among individuals are caused by numerous factors: differences in production and stability of mRNA of xenobiotic metabolizing enzymes, differences in the rate of enzyme synthesis and degradation, or enzyme inhibition. One of the most important reasons is genetic polymorphism of cytochrome P450 genes or cytochrome P450 regulatory factors. Nuclear receptors play great role in the regulation of these genes. The presence of the ligand induces the nuclear receptor to bind to the dimerisation partner and as a hetero/homodimer it can activate the DNA responsive element. In addition, several co-activators, co-repressors and other factors can modulate the effect of nuclear receptors. Hepatic levels of cytochrome P450 enzymes are reduced in multiple models of inflammation or infection. Cytochrome P450 enzymes of four families (CYP1-CYP4) are known to be involved in xenobiotic metabolism. Their genetic polymorphism and regulation are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504670     DOI: 10.1007/s00011-003-1186-4

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  7 in total

Review 1.  Role of xenobiotic metabolism in cancer: involvement of transcriptional and miRNA regulation of P450s.

Authors:  Viola Tamási; Katalin Monostory; Russell A Prough; András Falus
Journal:  Cell Mol Life Sci       Date:  2010-12-24       Impact factor: 9.261

Review 2.  The detoxification limitation hypothesis: where did it come from and where is it going?

Authors:  Karen J Marsh; Ian R Wallis; Rose L Andrew; William J Foley
Journal:  J Chem Ecol       Date:  2006-05-23       Impact factor: 2.626

3.  Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.

Authors:  Stella Koutros; Gabriella Andreotti; Sonja I Berndt; Kathryn Hughes Barry; Jay H Lubin; Jane A Hoppin; Freya Kamel; Dale P Sandler; Laurie A Burdette; Jeffrey Yuenger; Meredith Yeager; Michael C R Alavanja; Laura E Beane Freeman
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

4.  Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism.

Authors:  László Kóbori; Krisztina Kõhalmy; Pálma Porrogi; Enikõ Sárváry; Zsuzsa Gerlei; János Fazakas; Péter Nagy; Jenõ Járay; Katalin Monostory
Journal:  Br J Clin Pharmacol       Date:  2007-12-07       Impact factor: 4.335

5.  Development of a High-Resolution Melting Analysis Method for CYP2C19*17 Genotyping in Healthy Volunteers.

Authors:  Zahra Ghasemi; Mehrdad Hashemi; Mahsa Ejabati; Seyyed Meisam Ebrahimi; Hamidreza Kheiri Manjili; Ali Sharafi; Ali Ramazani
Journal:  Avicenna J Med Biotechnol       Date:  2016 Oct-Dec

6.  Use of computational toxicology tools to predict in vivo endpoints associated with Mode of Action and the endocannabinoid system: A case study with chlorpyrifos, chlorpyrifos-oxon and Δ9Tetrahydrocannabinol.

Authors:  Marilyn Silva; Ryan Kin-Hin Kwok
Journal:  Curr Res Toxicol       Date:  2022-02-07

7.  Systematic functional study of cytochrome P450 2D6 promoter polymorphisms in the Chinese Han population.

Authors:  Xueli Gong; Yichen Liu; Xiaoqing Zhang; Zhiyun Wei; Ran Huo; Lu Shen; Lin He; Shengying Qin
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.